In Vitro Chemosensitivity Testing of Primary and Recurrent Breast Carcinomas and Its Clinical Significance

被引:2
作者
Li, Zhi [1 ]
Song, Haiping [1 ]
He, Wenshan [1 ]
Tian, Yuan [1 ]
Huang, Tao [1 ]
机构
[1] Huazhong Univ Sci & Technol, Tongji Med Coll, Union Hosp, Dept Breast & Thyroid Surg, Wuhan 430022, Peoples R China
关键词
chemotherapy; breast cancer; primary culture; in vitro study;
D O I
10.1007/s11596-008-0616-5
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
In this study, in vitro chemosensitivity testing was conducted on primary cultured breast cancer cells from 96 patients with breast cancer, and the results showed that the cells from a few patients with primary breast cancer developed multidrug resistance (MDR) prior to the first chemotherapy exposure. All the cells from the recurrent cancer patients had MDR. The findings suggested that patients having MDR would benefit from high-dose chemotherapy (HDC) regimens. In vitro chemosensitivity screening, which was aimed at improving the therapeutic efficacy and minimizing side effects, helps in choosing individualized treatment for breast cancer.
引用
收藏
页码:683 / 687
页数:5
相关论文
共 33 条
  • [1] Gene expression profiles predict complete pathologic response to neoadjuvant paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide chemotherapy in breast cancer
    Ayers, M
    Symmans, WF
    Stec, J
    Damokosh, AI
    Clark, E
    Hess, K
    Lecocke, M
    Metivier, J
    Booser, D
    Ibrahim, N
    Valero, V
    Royce, M
    Arun, B
    Whitman, G
    Ross, J
    Sneige, N
    Hortobagyi, GN
    Pusztai, L
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (12) : 2284 - 2293
  • [2] MDR1, chemotherapy and chromatin remodeling
    Baker, EK
    El-Osta, A
    [J]. CANCER BIOLOGY & THERAPY, 2004, 3 (09) : 819 - 824
  • [3] Global gene expression changes during neoadjuvant chemotherapy for human breast cancer
    Buchholz, TA
    Stivers, DN
    Stec, J
    Ayers, M
    Clark, E
    Bolt, A
    Sahin, AA
    Symmans, WF
    Hess, KR
    Kuerer, HM
    Valero, V
    Hortobagyi, GN
    Pusztai, L
    [J]. CANCER JOURNAL, 2002, 8 (06) : 461 - 468
  • [4] CHARLOTTE K, 2004, PNAS, V101, P4966
  • [5] The evolution of treatment strategies: Aiming at the target
    Dinh, Phuong
    Sotiriou, Christos
    Piccart, Martine J.
    [J]. BREAST, 2007, 16 : S10 - S16
  • [6] A multidrug resistance transporter from human MCF-7 breast cancer cells
    Doyle, LA
    Yang, WD
    Abruzzo, LV
    Krogmann, T
    Gao, YM
    Rishi, AK
    Ross, DD
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1998, 95 (26) : 15665 - 15670
  • [7] Polymer-drug conjugates: towards a novel approach for the treatment of endrocine-related cancer
    Duncan, R
    Vicent, MJ
    Greco, F
    Nicholson, RI
    [J]. ENDOCRINE-RELATED CANCER, 2005, 12 : S189 - S199
  • [8] Chemosensitization of cancer in vitro and in vivo by nitric oxide signaling
    Frederiksen, Lisa J.
    Sullivan, Richard
    Maxwell, Lori R.
    Macdonald-Goodfellow, Shannyn K.
    Adams, Michael A.
    Bennett, Brian M.
    Siemens, D. Robert
    Graham, Charles H.
    [J]. CLINICAL CANCER RESEARCH, 2007, 13 (07) : 2199 - 2206
  • [9] Gilbert SG, 2006, NEW ENGL J MED, V354, P640
  • [10] The emerging pharmacotherapeutic significance of the breast cancer resistance protein (ABCG2)
    Hardwick, L. J. A.
    Velamakanni, S.
    van Veen, H. W.
    [J]. BRITISH JOURNAL OF PHARMACOLOGY, 2007, 151 (02) : 163 - 174